SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 24, 2003
BioTransplant Incorporated
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-28324 |
|
04-3119555 |
|
(State or other
jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
|
|
|
|
|
|
200
Boston Avenue |
|
|
|
02129 |
|
(Address of principal |
|
|
|
(Zip Code) |
Registrant’s telephone number, including area code: 781-393-8500
N/A
(Former name or former address, if changed since last report)
|
Item 5. |
Other Events. |
On April 24, 2003, BioTransplant Incorporated (the "Company") issued a press release providing an update on the clinical development status of MEDI-507, the Company's monoclonal antibody which has been licensed to MedImmune, Inc.
See the press release attached hereto as Exhibit 99.1.
|
Item 7. |
Financial Statements, Pro Forma Financial Information and Exhibits. |
(c) Exhibits.
See Exhibit Index attached hereto.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: |
April 25, 2003 |
BIOTRANSPLANT INCORPORATED |
||
|
|
|
|
||
|
|
By: |
/s/ Donald B. Hawthorne |
|
|
|
|
|
Donald B. Hawthorne |
||
|
|
|
President, Chief Executive Officer and |
||
3
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
Exhibit 99.1 |
|
Press Release dated April 24, 2003 |
4